Otsuka strikes licensing deal of diabetes therapy

Otsuka Pharmaceutical has licensed the Japanese rights to Bristol-Myers Squibb's saxagliptin, being studied for the treatment of Type 2 diabetes. BMS gets an upfront payment and a schedule of milestones. Saxagliptin, discovered by Bristol-Myers Squibb, is a dipeptidyl peptidase-4 (DPP-4) inhibitor currently in Phase III development in the United States and Europe.

- here's the report on the deal from MedicalNewsToday

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.